Perifosine is a novel oral inhibitor of Akt which is currently in phase 3 clinical trials and importantly, it has been shown to inhibit the phosphorylation of Akt and downstream mTOR and p70 S6K in various NSCLC cell lines [49]. Here, AKT1 is linked to non-small cell lung carcinoma.